It is made available under a CC-BY 4.0 International license .

# 1 Chronic respiratory symptoms and chronic obstructive pulmonary disease following

# 2 completion of pulmonary tuberculosis treatment in Uganda

- 3 Martha Namusobya<sup>1</sup>, Felix Bongomin<sup>2,3</sup>, Mukisa John<sup>4</sup>, Ivan Kimuli<sup>5</sup>, Ahmed Ddungu<sup>6</sup>, Charles
- 4 Batte<sup>5</sup>, Bruce J. Kirenga<sup>5</sup>
- 5 Author affiliations:
- 6 1. Department of Clinical Epidemiology and Biostatistics, School of Medicine, College of
- 7 Health Sciences, Makerere University, Kampala, Uganda
- 8 2. Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu
- 9 University, Gulu, Uganda
- 10 3. Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health,
- 11 University of Manchester, M13 9PL, Oxford Road, Manchester, United Kingdom
- 4. Department of Immunology and Molecular Biology, School of Biomedical Sciences,

13 College of Health Sciences, Makerere University, Kampala, Uganda.

- 14 5. Makerere Lung Institute, School of Medicine, College of Health Sciences, Makerere
- 15 University, Kampala, Uganda
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala,
   Uganda
- 18
- 19 Correspondence to Dr. Martha Namusobya, Department of Clinical Epidemiology and
- 20 Biostatistics, School of Medicine, College of Health Sciences, Makerere University, Kampala,
- 21 Uganda. Email: <u>martharynam@gmail.com</u>

It is made available under a CC-BY 4.0 International license .

#### 23 Abstract

#### 24 Background

- 25 Prior pulmonary tuberculosis (PTB) is associated with chronic lung impairment, including
- 26 chronic obstructive pulmonary disease (COPD). We determined the prevalence and
- 27 associations of chronic respiratory symptoms and COPD following completion of PTB treatment
- in Uganda.

# 29 Methods

- 30 Between August 2022 and December 2022, we consecutively enrolled post-PTB patients who
- had successfully completed PTB treatment between January 2016 and January 2020 at Mulago

32 National Referral Hospital, Kampala, Uganda. Chronic respiratory symptoms were defined as

the presence of at least one of the following symptoms lasting for at least three months within a

- 34 year: cough or sputum production, shortness of breath, chest pain, or wheezing, along with an
- 35  $FEV_1/FVC < 0.70$  on spirometry for the definition of COPD.

#### 36 Results

37 We enrolled 326 participants (median age 36 years; IQR: 30 – 43), 182 (55.8%) were male, and 123 (37.7%) were living with HIV. Fifty-one (15.6%) participants had chronic respiratory 38 39 symptoms, 5 (9.8%) having COPD; 4 GOLD I and 1 GOLD II. Chronic respiratory symptoms were 89% lower among participants whose PTB treatment outcome was "completed" (adjusted 40 41 Odds Ratio (aOR): 0.11, 95% confidence interval (CI): 0.01 - 0.87, p<0.01) and they were 74% lower among those with alcohol use disorders (aOR: 0.26, 95% CI: 0.12 – 0.57, p < 0.001). Non-42 HIV immunosuppressive conditions such as diabetes mellitus and chronic steroid use, were 43 44 significantly associated with both chronic respiratory symptoms (aOR:7.72, 95% CI 3.13 -45 19.04, p<0.001) and COPD (aOR: 8.42, 95% CI: 1.32 - 53.47, p=0.024).

It is made available under a CC-BY 4.0 International license .

# **Conclusion**

- 47 Chronic pulmonary symptoms, including COPD, are important and yet under recognized
- 48 complications of PTB treatment in Uganda. Therefore, screening and management in key sub-
- 49 groups, such as those with immunosuppressive condition, will improve morbidity and quality of
- 50 life in this population.

# 52 Keywords

- 53 Pulmonary tuberculosis, Chronic Respiratory Symptoms, Chronic Obstructive Pulmonary
- 54 Disease, Spirometry, Uganda.

- ...

It is made available under a CC-BY 4.0 International license .

#### 68 Introduction

69 Pulmonary tuberculosis (PTB) is associated with parenchymal destruction leading to alteration 70 in lung architecture and chronic lung impairment, including chronic obstructive pulmonary disease (COPD). Many patients remain symptomatic even after 'successful' PTB treatment (1). 71 72 Studies done in Brazil and Malawi showed that prevalence of chronic respiratory symptoms 73 after PTB cure were 45% (2) and 30.7% (3), respectively. The PLATINO study showed that the overall prevalence of airflow obstruction is over 2-folds higher among subjects with a history of 74 75 tuberculosis(TB), compared to those without TB history (4). In this study, a history of prior TB 76 was associated with a more severe form of COPD (4).

77 COPD is one of the common complications of PTB (1,6,8). A cross-sectional study done among 78 cured Ugandan drug-resistant (DR) TB patients found a 23% prevalence of COPD(5). This 79 study didn't include drug-sensitive (DS) TB patients who comprise the majority of TB patients. Another study in Ethiopia showed the prevalence of COPD among successfully treated PTB 80 81 patients (both DS and DR) to be 41.4% (6). The symptoms of COPD (chronic cough, dyspnea, frequent respiratory infections, fatigue, and wheezing) are similar to PTB symptoms and may 82 plague TB patients long after cure. This may be misdiagnosed as a TB recurrence, and 83 84 managed inappropriately. This may in turn negatively impact patients' guality of life, leading to 85 increased morbidity, hospital visits, and mortality (7).

COPD is the third leading cause of death worldwide (11), causing 3.23 million deaths in 2019
(13). Over 80% of these deaths occurred in low- and middle-income countries (LMICs) (8).
COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing,
cough, and/or phlegm production (8). A study conducted in Malawi showed that at PTB
completion, 60.7% of participants reported respiratory symptoms, and 34.2% had abnormal
spirometry(3). With such staggering statistics, and paucity of data in our own setting, Uganda; it
will be key to not only quantify the burden of post-TB persistent respiratory symptoms and

It is made available under a CC-BY 4.0 International license .

COPD, but also tease out their associations. COPD is manageable, and therefore early
diagnosis in this special population will be key in reducing morbidity, mortality, and informing
management to improve long term outcomes (9, 10).

The TB burden in Uganda remains high with a prevalence of 197 per 100,000 population (11), 96 thus predisposing many patients to the risk of developing chronic lung disease. TB sequelae 97 98 include obstructive and restrictive lung diseases, bronchiectasis, pleural disease among others (5, 12). Therefore, we hypothesized that COPD is highly prevalent among Ugandan adults who 99 have chronic pulmonary symptoms after PTB treatment. The aim of this study was threefold: to 100 101 determine the prevalence of chronic respiratory symptoms after PTB treatment, assess the prevalence of COPD among participants with these symptoms following successful PTB 102 103 treatment, and identify factors associated with chronic respiratory symptoms and COPD in this 104 population.

105

#### 106 METHODS

#### 107 Study design

We conducted a cross-sectional study at the National TB Control Center at Mulago National
 Referral Hospital (MNRH), Kampala, Uganda between 1<sup>st</sup> August 2022 and 30<sup>th</sup> November
 2022.

#### 111 Study Setting

The TB Unit at MNRH serves as the national TB treatment center in Uganda. The unit uses a mixed model of care, whereby, 1) very sick patients are hospitalized at the start of their TB treatment until clinically stable, and 2) outpatient care where patients continue treatment from

It is made available under a CC-BY 4.0 International license .

the community under supervision. The unit manages about 1,500 TB patients annually, makingit the largest treatment center in the country.

#### 117 Study population

- 118 We enrolled post-PTB patients, both drug-sensitive (DS) and drug resistant (DR), 18 years and
- older, who cured or completed treatment between January 2016 and January 2020, and whose
- 120 PTB treatment enrollment dates fell in the 2 randomly selected quarters of each cohort year.
- 121 Pregnant women, critically ill people, those previously treated for only extra-pulmonary TB,
- those with active TB (relapses), and those with history of heart disease were excluded.

#### 123 Sample size estimation

- 124 Using previous data of a 30.7% prevalence of persistent pulmonary symptoms in the post-PTB
- population (3), at 95% confidence interval (CI), power of 80% and type I error of 5%, a sample
- size of 327 participants was estimated.

# 127 Study procedure

For all eligible participants, a trained medical officer collected data on clinical and demographic characteristics such as age, sex, HIV status and other key co-morbidities e.g., asthma, clinical symptoms, alcohol and tobacco use, type of fuel used for cooking, the type of infrastructure in which cooking happens, occupation, income, and education status using a standardized structured questionnaire. Participants were consecutively recruited until required sample size was reached.

## 134 Spirometry

Participants with chronic respiratory symptoms as ascertained from the questionnaire had
spirometry done to assess for COPD. Spirometry was performed by a trained and experienced

It is made available under a CC-BY 4.0 International license .

137 spirometry technician and read and interpreted by a pulmonologist at the Makerere University

Lung Institute (MLI). MLI is a center of excellence in innovative lung health research that

- 139 integrates disease prevention, clinical care and training.
- 140 COPD can be estimated with a high diagnostic accuracy using spirometry (13, 14). The
- sensitivity for diagnosing airway obstruction in COPD using spirometry is 92% and specificity is
- 142 84% (15). The positive predictive value (PPV) is 63%; negative predictive value (NPV) is 97%
- 143 (15). A spirometry value of  $FEV_1/FVC < 0.70$  confirmed the presence of persistent airflow
- 144 limitation (COPD) (16). The severity of COPD was classified using the Global Initiative for
- 145 Chronic Obstructive Lung Disease (GOLD) classification (17).

#### 146 Data analysis

147 Participant characteristics that were in form of continuous data were described using medians

and interquartile ranges. Categorical data was presented in frequencies, proportions and

149 percentages. Comparison between the different categories (e.g. chronic respiratory symptoms

150 vs no chronic respiratory symptoms and COPD vs no COPD) were made using chi square test

151 while continuous variable comparisons were done using the Wilcoxon Rank Sum test. Pie

152 charts and box plots were drawn for data visualization.

153 The prevalence of chronic respiratory symptoms after successful PTB treatment was presented

as proportions/percentages of individuals with any of the symptoms as per the operational

definition. Subgroup analysis was performed considering gender as a possible cause of

difference in prevalence of chronic respiratory symptoms.

157 The prevalence of COPD among participants with chronic respiratory symptoms after successful

158 PTB treatment was determined by spirometry evaluation. This was categorized as a

dichotomous variable and data was presented as percentages and pie charts. Subgroup

It is made available under a CC-BY 4.0 International license .

analysis was performed considering gender as a possible cause of difference in prevalence ofCOPD.

162 To determine factors associated with chronic respiratory symptoms after successful PTB treatment, the presence of chronic respiratory symptoms was dichotomized into a 1 "ves" 0 "No" 163 164 variable. We tested for assumptions for collinearity and outliers before running a logistic 165 regression model. A bivariate analysis was carried out between the study independent variables and the presence of chronic respiratory symptoms. Factors with biological plausibility from 166 167 literature like age and sex and those with P< 0.25 will be considered for further multivariable regression analysis. Interaction will be assessed by forming two-way interaction terms and using 168 169 the likelihood ratio test to assess significance of the interaction terms. Confounding will be assessed by considering a change of 10% percent or more in the odds ratios as confounding, 170 when a model with the variable and one without it are evaluated. The goodness of fit of the final 171 model will be assessed using the Hosmer-Lemeshow goodness of fit statistics. The odds ratios 172 173 and their 95 % confidence intervals will be presented. A p<.05 will be considered statistically significant. STATA version 14.0 was used for data analysis. 174

To determine factors associated COPD after successful PTB treatment, the presence of COPD
was dichotomized into a 1 "yes" 0 "No" variable and the process of logistic regression above
was repeated but this time with COPD as the outcome variable.

178 Ethics

The Makerere University School of Biomedical Science Research and Ethics Committee (SBS-2022-131) and the Uganda National Council for Science and Technology (HS2232ES) approved the study protocol. All study participants provided informed written consent. The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to.

It is made available under a CC-BY 4.0 International license .

#### 184 Results

# 185 **Baseline characteristics of the participants**

- 186 Of the 326 participants enrolled, 182 (55.8 %) were male with a median age for all participants
- of 36 (IQR: 30 43) years. One hundred and twenty-three (37.7%) participants were living with
- 188 HIV. Majority of the participants, 206 (63.2%), had received Category 1 PTB treatment. A
- significant number of participants, 145 (44.5%), had history of alcohol use and 66 (20.2%) had a
- 190 history of smoking tobacco. Twenty-six (8%) of participants had history of other
- 191 immunosuppressive conditions other than HIV (particularly diabetes and chronic steroid use).
- 192 Thirteen (4%) of participants reported history of childhood measles. There were 6 (1.8%)
- 193 participants with history of asthma. Four (1.2%) participants had history of severe childhood
- respiratory infections e.g., pneumonia. Only 1 (0.3%) participant had history of COPD, lung
- cancer and sarcoidosis each. Majority of participants, 274 (84%), used charcoal as their main
- source of cooking fuel, whilst majority (46.3%) cooked in kitchens attached to the main house.
- 197 (**Table 1**).

198

## 199 Table 1. Baseline characteristics

Characteristic	Frequency	Percentage %	Median and IQR
Sex			
male	182	55.8	
female	144	44.2	
Age			
Median, IQR			36 (30-43)
<40	215	65.9	
40-49	78	23.9	
50 and above years	33	10.2	
PTB treatment regimen/ category			
Category 1	206	63.2	

It is made available under a CC-BY 4.0 International license .

Category 2	1	0.3
Category 4 (DR TB treatment)	119	36.5
HIV diagnosis		
Positive	123	37.7
Negative	200	61.3
Unknown	3	0.9
Mycobacteria other than tuberculosis history		
Yes	1	0.3
No	325	99.7
Asthma history		
Yes	6	1.8
No	320	98.2
COPD history		
Yes	1	0.3
No	325	99.7
Sarcoidosis history		
Yes	1	0.3
No	325	99.7
Lung cancer history		
Yes	1	0.3
No	325	99.7
Chicken pox history		
Yes	7	2.1
No	319	97.9
Alcoholism history		
Yes	145	44.5
No	181	55.5
Any other immunosuppressive conditions other than HIV (e.g. diabetes mellitus, and chronic steroid use) history		
Yes	26	8
No	300	92
Smoking history		
Yes	66	20.2
No	260	79.8
Measles history		
Yes	13	4
No	313	96
History of severe childhood respiratory infections e.g. pneumonia		
Yes	4	1.2
No	322	98.8

It is made available under a CC-BY 4.0 International license .

# 201

# 202 Prevalence of chronic respiratory symptoms.

- 203 Of 326 participants, 51 (15.6%) reported at least one of the chronic respiratory symptoms as per
- case definition. Forty-eight (14.7%) reported shortness of breath, 31 (9.5%) reported cough, 30
- 205 (9.2%) reported chest pain, while 22 (6.7%) reported wheezing, (**Table 2**).

#### **Table 2. Prevalence of chronic respiratory symptoms**

		Male N(%)	Female,	P value
Characteristic	Total, N(%)		N(%)	
Persistent cough				
Yes	31 (9.5)	13 (7.1)	18( 12.5)	
No	295 (90.5)	169 (92.9)	126 (87.5)	0.102
Shortness of breath				
Yes	48 (14.7)	21 (11.5)	27 (18.8)	
No	278 (85.3)	161 (88.5)	117 (81.3)	0.068
Chest pain				
Yes	30 (9.2)	14 (7.7)	16 (11.1)	
No	296 (90.8)	168 (92.3)	128 (88.9)	0.289
Wheezing				
Yes	22 (6.7)	6 (3.3)	16 (11.1)	
No	304 (93.3)	176 (96.7)	128 (88.9)	0.005
No symptoms	275 (83.4)	162 (87.9)	112 (77.8)	0.015

<sup>207</sup> 

- At multivariable analysis, factors that were statistically significantly associated with chronic
- 209 respiratory symptoms were: participants whose successful PTB treatment outcome was
- 210 "completed treatment" (aOR: 0.11, 95%CI: 0.01 0.87, p=0.037), having any other
- immunosuppressive conditions other than HIV (e.g. diabetes mellitus, and chronic steroid use)
- 212 (aOR: 7.72, 95%CI: 3.13 19.04, p<0.001), and a history of alcoholism (aOR: 0.26, 95%CI:
- 213 0.12 0.57, p=0.001), (**Table 3**).

# Table 3. Multivariate analysis of the independent variables to determine their association

# 216 with presence of chronic pulmonary symptoms.

	Adjusted odds ratio and 95	
Characteristic	% CI	P value
PTB treatment outcome		
Cured	Ref	
Completed	0.11 (0.01-0.87)	0.037
Any other immunosuppressive conditions other than HIV (e.g. Diabetes mellitus		
No	Ref	
Yes	7.72(3.13-19.04)	<0.001
Alcoholism		
No	Ref	
Yes	0.26 (0.12-0.57)	0.001
Age in completed years		
<40	Ref	
40-49	1.54(0.72-3.33)	0.268
50 and above years	1.90 (0.67-5.37)	0.226

217

# 218 **Prevalence of COPD**

In the 51 (15.6%) participants with chronic respiratory symptoms in whom spirometry was

indicated, 5 (9.8%) had COPD. Of the 5 participants with COPD, 4 (80%) had a classification of

- 221 GOLD I while 1 (20%) had a classification of GOLD II. Other ventilatory defects on spirometry
- were: asthma (n=10, 19.6%), and restrictive lung disease (n=3, 5.9%), **Table 4**.

# Table 4. Prevalence of COPD and other findings on spirometry.

224 **N=51** 

Characteristic	Frequency	Percentage
COPD	5	9.8
Asthma	10	19.6
Restriction	3	5.9
Normal spirometry	33	64.7

225

It is made available under a CC-BY 4.0 International license .

- 227 At multivariable analysis, COPD was independently associated with having other
- immunosuppressive conditions other than HIV (e.g., diabetes mellitus, and chronic steroid use)
- 229 (aOR: 8.42, 95%CI: 1.32 53.47, p=0.024), (**Table 5**).

# Table 5. Multivariate analysis of the independent variables to determine their association with presence of COPD.

Characteristic	Adjusted odds ratio and 95 % Cl	P value
Other immunosuppressive conditions other than HIV (e.g. diabetes mellitus, chronic steroid use) history		
No	Ref	
Yes	8.42 (1.32-53.47)	0.024
Where do you cook from?		
Kitchen attached to main house	Ref	
Kitchen separate from the main house	0.88 (0.09-9.00)	0.915
Outdoors/other	0.38 (0.04-3.78)	0.409

<sup>232</sup> 

# 234 Discussion

- In this study, we found the prevalence of chronic respiratory symptoms among successfully
- treated post-TB patients to be 15.6%. Our findings are close in keeping with literature that has
- reported post-TB lung sequalae prevalence to range anywhere from 18 87% (18) among
- 238 successfully treated PTB patients.
- The prevalence of COPD among those with chronic respiratory symptoms was about 10%. This
- prevalence is lower than the 23% that was found when a cross-sectional study was conducted
- among cured Ugandan DR TB patients (5). This may likely be because the study recruited only
- 242 DR TB patients who make up the biggest population of PTB treatment failures and retreatments
- 243 (19) and who thus have worse lung sequalae and higher COPD prevalence.

<sup>233</sup> 

It is made available under a CC-BY 4.0 International license .

Chronic respiratory symptoms were independently associated with having other
immunosuppressive conditions other than HIV (e.g., diabetes mellitus, and chronic steroid use).
It's quite unsurprising that immunosuppressive states would cause chronic respiratory
symptoms because PTB is a driver for opportunist fungal pathogens e.g. chronic pulmonary
aspergillosis, which flourish in the immunosuppressed host to cause chronic pulmonary
symptoms (20, 21).

COPD was also independently associated with immunosuppressive conditions other than HIV 250 251 e.g., diabetes mellitus and chronic steroid use. Diabetes has been shown to have adverse 252 inflammatory effects on lung anatomy and physiology (22) and whose impact is inadvertently 253 amplified in conditions of concurrent lung damage like post-TB sequalae. Part of COPD 254 management is use of systemic or inhaled steroids which improve symptoms (23) and this might be why we saw an association with chronic steroid use. That possibly to relieve symptoms, 255 these post-TB patients had steroids prescribed whether by self or health workers, even in the 256 257 absence of a definitive COPD diagnosis, to improve their guality of life.

Despite a relatively high burden of chronic respiratory symptoms among the study participants, 258 COPD only contributed to about 10% of the etiology of these symptoms. Therefore, multiple 259 260 etiologies may explain chronic respiratory symptoms in the settings of post-PTB treatment. In 261 this study, we were able to show that asthma and restrictive lung disease contributed to an additional 25% of participants with chronic respiratory symptoms. We have previously shown 262 263 that chronic pulmonary aspergillosis (CPA) occurs in up to 20% of PTB patients with persistent symptoms (24), significantly affecting their quality of life during PTB treatment (25). Therefore, 264 265 investigations for both infectious complications and ventilatory defects are indicated in patients with chronic respiratory symptoms following completion of PTB treatment. 266

It is made available under a CC-BY 4.0 International license .

267 This study has some limitations. Firstly, this was a single center study, involving mainly patients 268 from the central region of Uganda and may not be representative of other populations since 269 epidemiological patterns may differ across populations. Secondly, we did not perform chest imaging such as chest x-ray or CT scan, which would be helpful to rule out other complications 270 271 of post-PTB such as CPA and other differential diagnosis. In addition, further evaluation 272 including sputum examination to rule out TB relapse and other intercurrent pulmonary infections were not done. However, we conducted a rigorous respiratory investigation including 273 274 spirometry, which is the gold standard for COPD diagnosis. Future, prospective, multicenter 275 studies are recommended to substantiate our findings and provide further insides into the 276 pathogenesis of chronic respiratory

#### 277 Conclusions

In conclusion, we demonstrated that chronic respiratory symptoms and COPD where of concern 278 279 in the post-TB patient population, particularly those with history of non-HIV immunosuppressive conditions such as diabetes mellitus and chronic steroid use. COPD is manageable, and 280 therefore early diagnosis in such special populations will be key in reducing morbidity, mortality, 281 and informing management to improve long term outcomes. Additionally, beyond just COPD, 282 283 other conditions like fungal pathogens may plaque post-TB patients and cause chronic 284 respiratory symptoms. These too should be screened for and appropriately managed among this patient population for improved outcomes and guality of life. 285

# 286 Acknowledgement

We thank the MNRH TB unit for hosting the study. We're grateful to the study team based there who were key in participant identification and recruitment. We're grateful to MLI who performed the study spirometry.

It is made available under a CC-BY 4.0 International license .

#### 290 Funding

- 291 This research was supported by the Makerere University Non-Communicable Diseases
- 292 (MAKNCD) Research Training Program that is supported by the Fogarty International Centre of
- the National Institutes of Health under Award Number D43TWO11401. The content is solely the
- responsibility of the authors and does not necessarily represent the official views of the National
- 295 Institutes of Health.
- 296 Disclosure
- 297 There is no conflict of interest to disclose.

#### 298

#### 299 REFERENCES

Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary
 tuberculosis treatment: A quest for a public health approach. Journal of Clinical Tuberculosis and Other
 Mycobacterial Diseases. 2016;3:10-2.

Nihues SdSE, Mancuzo EV, Sulmonetti N, Sacchi FPC, de Souza Viana V, Netto EM, et al. Chronic
 symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients. The Brazilian Journal of
 Infectious Diseases. 2015;19(5):492-7.

Meghji J, Lesosky M, Joekes E, Banda P, Rylance J, Gordon S, et al. Patient outcomes associated
 with post-tuberculosis lung damage in Malawi: a prospective cohort study. Thorax. 2020;75(3):269-78.
 Sarkar M, Srinivasa, Madabhavi I, Kumar K. Tuberculosis associated chronic obstructive

309 pulmonary disease. The Clinical Respiratory Journal. 2017;11(3):285-95.

Nuwagira E, Stadelman A, Baluku JB, Rhein J, Byakika-Kibwika P, Mayanja H, et al. Obstructive
 lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-

sectional study. Tropical Medicine and Health. 2020;48(1):34.

Amsalu Bekele MG, Charles B. Sherman, Neil W. Schluger. Prevalence of chronic obstructive
 pulmonary disease (COPD) among patients successfully treated for pulmonary tuberculosis in Ethiopia.
 Ethiopian Medical Journal. 2020;58(April).

- 316 7. Sandelowsky H, Weinreich UM, Aarli BB, Sundh J, Høines K, Stratelis G, et al. COPD do the right
   317 thing. BMC Family Practice. 2021;22(1).
- 318 8. Organisation WH. Chronic pulmonary Aspergillosi. 2021:5.

319 9. Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD.

- 320 Respiratory Research. 2017;18(1).
- 10. Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, et al. Understanding

the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life.

- European Journal of Internal Medicine. 2020;73:1-6.
- 11. Ministry of Health U. The National TB and Leprosy Survey. 2022.

It is made available under a CC-BY 4.0 International license .

Baig IM, Saeed W, Khalil KF. Post-tuberculous chronic obstructive pulmonary disease. J Coll
 Physicians Surg Pak. 2010;20(8):542-4.

Bosse CG, Criner GJ. Using spirometry in the primary care office. A guide to technique and
 interpretation of results. Postgrad Med. 1993;93(5):122-4, 9-30, 33-6 passim.

14. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: a systematic review and meta-analysis. BMJ Open. 2015;5(10):e008133.

Schneider A, Gindner L, Tilemann L, Schermer T, Dinant GJ, Meyer FJ, et al. Diagnostic accuracy
 of spirometry in primary care. BMC Pulm Med. 2009;9:31.

16. Disease GIFCOL. Global Strategy for the Diagnosis, Management, and Prevention of Chronic
 Obstructive Pulmonary Disease. 2021:164.

335 17. (GOLD) GIFCOLD. 2023 GOLD Report. 2023.

18. Allwood BW, van der Zalm MM, Amaral AFS, Byrne A, Datta S, Egere U, et al. Post-tuberculosis
lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis. 2020;24(8):8208.

339 19. Organization WH. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva,
 340 Switzerland; 2019.

Bongomin F. Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health
 concern. PLoS Pathog. 2020;16(8):e1008742.

Rozaliyani A, Rosianawati H, Handayani D, Agustin H, Zaini J, Syam R, et al. Chronic Pulmonary
Aspergillosis in Post Tuberculosis Patients in Indonesia and the Role of LDBio Aspergillus ICT as Part of
the Diagnosis Scheme. J Fungi (Basel). 2020;6(4).

22. Gunasekaran K, Murthi S, Elango K, Rahi MS, Thilagar B, Ramalingam S, et al. The Impact of

Diabetes Mellitus in Patients with Chronic Obstructive Pulmonary Disease (COPD) Hospitalization. J Clin
 Med. 2021;10(2).

Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive
 pulmonary disease. Proc Am Thorac Soc. 2008;5(4):506-12.

351 24. Namusobya M, Bongomin F, Mukisa J, Olwit WK, Batte C, Mukashyaka C, et al. Chronic

pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in
 Uganda. Mycoses. 2022;65(6):625-34.

35425.Namusobya M, Bongomin F, Mukisa J, Batte C, Olwit WK, Rhein J, et al. The Impact of Chronic355Pulmonary Aspergillosis Co-infection on the Health-Related Quality of Life of Patients with Pulmonary

356 Tuberculosis in Uganda. Mycopathologia. 2023.